Skip to content Skip to footer
Subscribe Now
NEWS

Novanta to Acquire Riverpoint Medical in ~$1.45B Deal

Shots: Novanta has entered into a definitive agreement to acquire Riverpoint Medical from Arlington Capital Partners, expanding Novanta’s presence in the minimally invasive surgery market As per the deal, Novanta will acquire Riverpoint for $1.2B upfront, with $250M in milestone payments expected in Q1’27, representing the total deal value of $1.45B; closing is anticipated in…
15 hours ago

Read more

NEWS

Johnson & Johnson to Acquire Firefly Bio for $1B

Shots: J&J has entered into a definitive agreement to acquire Firefly Bio, incl. its Firelink degrader antibody conjugate (DAC) platform, expanding its oncology pipeline As per the deal, J&J will acquire Firefly Bio for $1B in cash, with closing expected later this year The Firelink DAC platform is a targeted protein degradation tech that selectively…
20 hours ago

Read more

NEWS

Incyte to Acquire Vega Therapeutics for ~$2B

Shots: Incyte has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, to expand its hematology portfolio into bleeding disorders As per the deal, Incyte will acquire Vega for $1.25B upfront, with ~$750M in additional payments upon achievement of sales milestones Acquisition will expand Incyte’s hematology portfolio with…
2 days ago

Read more

NEWS

Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business for ~$2.65B

Shots: Servier has entered into an agreement with Edgewise Therapeutics to acquire its muscular dystrophy business, supporting Servier’s strategic ambition in rare neurology As per the deal, Servier will acquire the muscular dystrophy business for ~$2.65B, incl. $1.55B upfront and ~$1.1B in regulatory & commercial milestone payments; closing is expected in Q3’26 The acquisition adds Edgewise’s…
June 2, 2026

Read more

NEWS

Eli Lilly Builds Infectious Disease Pipeline With 3 Acquisitions Valued ~$3.8B

Shots: Eli Lilly will acquire 3 companies, Curevo, LimmaTech Biologics, & Vaccine Company, to build its infectious disease portfolio through differentiated vaccine & platform technologies The deals incl. Curevo’s P-II shingles vaccine candidate amezosvatein, LimmaTech’s P-I vaccine LTB-SA7 targeting S. aureus infections, & Vaccine Company’s preclinical EBV vaccine platform leveraging proprietary in vivo nanoparticle technology As…
May 26, 2026

Read more

NEWS

Olympus to Acquire BioProtect for ~$270M

Shots: Olympus has entered into a definitive agreement to acquire BioProtect, incl. its Balloon Spacer system designed to protect healthy tissue during prostate cancer radiotherapy As per the agreement, Olympus will acquire BioProtect in a deal valued at ~$270M, with certain amounts held in escrow subject to uninterrupted business operations; closing is expected by the…
May 26, 2026

Read more

NEWS

Zydus to Acquire Assertio in ~$166.4M All-Cash Deal

Shots: Assertio Holdings’ Board has approved a definitive agreement with Zydus Worldwide DMCC, a subsidiary of Zydus, to acquire all outstanding Assertio shares, delisting it from the Nasdaq Assertio’s Board determined Zydus’ proposal constituted a “Superior Proposal” under the Garda merger agreement & authorized termination of the Garda transaction As per the deal, Zydus will…
May 14, 2026

Read more

NEWS

Roche to Acquire PathAI for ~$1.05B

Shots: Roche has entered into a definitive merger agreement to acquire PathAI, building on their 2021 partnership, which scaled up in 2024 to incl. the development of AI-enabled companion diagnostic algorithms As per the deal, Roche will acquire PathAI for $750M upfront & ~$300M in additional milestone payments; closing is expected in H2’26 The acquisition…
May 7, 2026

Read more

Load more